BMY Bristol-Myers Squibb Company

51.83
+0.27  (+1%)
Previous Close 51.56
Open 51.64
Price To Book 5.28
Market Cap 84,781,779,250
Shares 1,635,766,530
Volume 7,441,755
Short Ratio 16.54
Av. Daily Volume 10,034,431
Stock charts supplied by TradingView

NewsSee all news

  1. Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.S

    In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royaltiesCoeptis Pharmaceuticals has engaged a distribution partner with an established sales

  2. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  3. Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board

    Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company

  4. Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer

    Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels Median duration of response for patients treated with Opdivo

  5. Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

    52% of patients treated with Opdivo plus Yervoy were alive at five years 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free Results represent longest follow-up to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 1H 2021.
CM-649 – Opdivo+ Yervoy or Chemo
Gastric cancer
Phase 2 data April 25, 2019 did not meet primary endpoints.
CM-714 Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 1/2 updated data due at SITC November 9, 2019, 5:15 p.m.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Late-breaker at SITC November 11, 2017. ORR 14-32%.
BMS-986205 and Nivolumab
Advanced tumors
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrolment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Approval announced March 6, 2018.
Opdivo - 4 week applications
Approval announced November 10, 2017.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia
Approval announced July 6, 2017.
ORENCIA
Psoriatic Arthritis (PsA)
Phase 1/2 preliminary data presented at ASCO June 2, 2017. ORR=21%.
CM-358 – Opdivo
Cervical, vaginal and vulvar cancers
Phase 1/2 ORR rate of 12.5% noted at ASCO June 3, 2017.
BMS-986016 - LAG-3 + Opdivo
Melanoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approved under priority review September 22, 2017.
Opdivo (CM-040)
Previously Treated Hepatocellular Carcinoma
Phase 2 data due 2018.
TG4010 and Opdivo
Non-squamous non-small cell lung cancer (NSCLC)
Phase 2 late breaker at ASCO June 5, 2017. Control rate 44%. ORR 19%.
Opdivo + Yervoy
Malignant pleural mesothelioma (MPM)
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Approval announced August 1, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 first overall survival (OS) positive data released April 3, 2017
CM - 067 Opdivo in combination with Yervoy
Melanoma
Phase 3 data due early 2020.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Phase 3 data released January 19, 2017.
Opdivo - ONO-4538-12
Gastric cancer
Phase 2 presentation at AACR Meeting April 16, 2018.
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 1H 2021.
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 trial did not meet primary endpoint - June 24, 2019.
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 ongoing.
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 trial did not meet primary endpoint - November 26, 2018.
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 data released October 12, 2018 - primary endpoint not met.
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 interim data released June 6, 2017 - primary endpoint met. Data presented at ESMO September 10, 2017 - HR 0.65 compared to Yervoy. FDA Approval announced December 20, 2017.
CM-238 – Opdivo (Adjuvant)
Melanoma
Approved April 16, 2018.
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
Phase 3 data from Part 1 met primary endpoint; Part 2 missed primary endpoint.
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3 trial met primary endpoint - November 30, 2017.
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Urothelial Carcinoma - Bladder cancer
Opdivo (nivolumab)
Bladder cancer
Approval announced July 11, 2018.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
FDA approval announced August 17, 2018.
CM-32 - Opdivo+chemo
Small cell lung cancer (SCLC)
Phase 3 clinical hold lifted June 1, 2018.
CM-602 – Opdivo + pomalidomide and dexamethasone
Multiple Myeloma
FDA approval announced November 6, 2018.
Empliciti (elotuzumab) - ELOQUENT-3
Relapsed/refractory multiple myeloma
FDA Approval announced January 2, 2019.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 2 trial to be initiated 2Q 2019.
IPI-549 + Nivolumab (MARIO-275)
Urothelial cancer
Phase 3 data due 1H 2020.
CM-648 Opdivo + Yervoy
Esophageal Cancer
Phase 3 data due 2H 2021
CM-901 Opdivo + Yervoy
Urothelial Cancer
Phase 3 data due 2020.
CM-274 Opdivo (nivolumab)
Bladder cancer
Phase 3 data due 2020.
CM-577 - Opdivo
Esophageal cancer
Phase 3 data due 2H 2019.
CM-743 Opdivo + Yervoy
Mesothelioma
Phase 3 data due 2020.
Opdivo (nivolumab) and Ipilimumab (Yervoy) CM-915
Melanoma
Phase 3 trial did not meet PFS endpoint. Trial to continue to allow OS endpoint to mature - September 5, 2019.
CM-548 - Opdivo
First-line Glioblastoma (GBM) cancer
Phase 3 data due 2022.
CM-914 Opdivo in combination with Yervoy
Renal Cell Carcinoma
Phase 3 data due 2020.
CM-9LA Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released May 9, 2019 did not meet primary endpoint.
CM-498 Opdivo
Phase 3 data due 2H 2019.
Phase 3 trial initiation announced May 1, 2019.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma
Phase 2 presentation at EHA June 15, 2019.
ADCETRIS and Opdivo CM-744
Relapsed/Refractory Classical Hodgkin Lymphoma

Latest News

  1. Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.S

    In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royaltiesCoeptis Pharmaceuticals has engaged a distribution partner with an established sales

  2. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  3. Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board

    Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company

  4. Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer

    Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels Median duration of response for patients treated with Opdivo

  5. Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

    52% of patients treated with Opdivo plus Yervoy were alive at five years 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free Results represent longest follow-up to

  6. Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients

     Three-year analysis from Phase 3 CheckMate -238 study represents longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting Bristol-Myers Squibb Company (NYSE:BMY) today announced results of a three-year

  7. Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have...

    Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or

  8. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  9. Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights

    Bristol-Myers Squibb Company (NYSE:BMY) will host a webcast on Saturday, September 28, 2019 at 7:30 p.m. CEST (1:30 p.m. EDT) to discuss data presented at the European Society of Medical Oncology, in Barcelona, Spain.

  10. Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers

    Overall survival data from CheckMate -227 Part 1 evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in advanced non-small cell lung cancer featured in ESMO Presidential Symposium Five-year survival data

  11. Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019

    Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2019 on Thursday, October 31, 2019. During a conference call at 8:30 a.m. ET on October 31, company executives will review financial

  12. Bristol-Myers Squibb Board Announces Election of Three New Directors

    Mr. Michael Bonney, Dr. Julia A. Haller and Ms. Phyllis Yale to Join BMS Board as Independent Directors

  13. Bristol‑Myers Squibb Announces Dividend

    The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.41) per share on the $.10 par value Common Stock of the corporation. The next quarterly

  14. Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients

    Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated a greater than five-fold increase in five-year overall survival rates; 13.4% for

  15. Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance

    Data validates NT-219 mechanism of action in reversing resistance to various FDA-approved treatments in pancreatic tumor models of mice implanted with biopsies from patients (PDX) NT-219's novel mechanism

  16. Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

    Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the

  17. More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research

     10-year cancer survivor Dana Vaughns joins colleagues in cross-country cycling relay with a goal to raise more than $1 million for the V Foundation for Cancer Research Bristol-Myers Squibb Company (NYSE:BMY) employee

  18. BioMotiv and Bristol-Myers Squibb Form Strategic Partnership

    BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a new strategic

  19. Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference

    Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will

  20. Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference

    TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  21. European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

    Median progression-free survival and overall response rate doubled among patients receiving EPd compared to pomalidomide and low-dose dexamethasone alone Second Empliciti-based combination approved in Europe for

  22. Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology

    SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ multiplexed intratumoral microdosing platform, today announced